CN120399084A - Cd38和icam1抗体及其用途 - Google Patents

Cd38和icam1抗体及其用途

Info

Publication number
CN120399084A
CN120399084A CN202510567553.3A CN202510567553A CN120399084A CN 120399084 A CN120399084 A CN 120399084A CN 202510567553 A CN202510567553 A CN 202510567553A CN 120399084 A CN120399084 A CN 120399084A
Authority
CN
China
Prior art keywords
seq
present
cdr2
cdr3
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510567553.3A
Other languages
English (en)
Chinese (zh)
Inventor
刘滨
陈晓成
斯科特·比德林梅尔
伦纳德·波斯特
苏扬
李南炅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertosobinco
University of California San Diego UCSD
Original Assignee
Vertosobinco
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertosobinco, University of California San Diego UCSD filed Critical Vertosobinco
Publication of CN120399084A publication Critical patent/CN120399084A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202510567553.3A 2018-11-16 2019-11-15 Cd38和icam1抗体及其用途 Pending CN120399084A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862768566P 2018-11-16 2018-11-16
US62/768,566 2018-11-16
PCT/US2019/061884 WO2020102777A1 (en) 2018-11-16 2019-11-15 Cd38 and icam1 antibodies and uses thereof
CN201980089423.6A CN113302207B (zh) 2018-11-16 2019-11-15 Cd38和icam1抗体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980089423.6A Division CN113302207B (zh) 2018-11-16 2019-11-15 Cd38和icam1抗体及其用途

Publications (1)

Publication Number Publication Date
CN120399084A true CN120399084A (zh) 2025-08-01

Family

ID=70731683

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510567553.3A Pending CN120399084A (zh) 2018-11-16 2019-11-15 Cd38和icam1抗体及其用途
CN201980089423.6A Active CN113302207B (zh) 2018-11-16 2019-11-15 Cd38和icam1抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980089423.6A Active CN113302207B (zh) 2018-11-16 2019-11-15 Cd38和icam1抗体及其用途

Country Status (5)

Country Link
US (1) US12583932B2 (https=)
EP (1) EP3883967A4 (https=)
JP (2) JP7785284B2 (https=)
CN (2) CN120399084A (https=)
WO (1) WO2020102777A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12583932B2 (en) 2018-11-16 2026-03-24 Virtuoso Binco, Inc. CD38 and ICAM1 antibodies and uses thereof
US20220411508A1 (en) * 2019-09-09 2022-12-29 The Regents Of The University Of California Compositions and methods for making and using multispecific antibodies
JP2023526605A (ja) * 2020-05-14 2023-06-22 ヴィルトゥオーソ ビンコ，インク． ヒト化ｃｄ３８およびｉｃａｍ１抗体、ならびにそれらの使用
WO2023034416A2 (en) * 2021-09-01 2023-03-09 Virtuoso Binco, Inc. Anti-icam1 antibodies and uses thereof
WO2023055376A1 (en) * 2021-09-30 2023-04-06 Virtuoso Binco, Inc. Multispecific antibodies for targeting cd47 and icam1 and methods of use thereof
KR102711074B1 (ko) * 2021-10-26 2024-10-04 재단법인 아산사회복지재단 암 생존자 유래 항체 및 이의 용도
WO2024207177A1 (en) * 2023-04-04 2024-10-10 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250288611A1 (en) * 2024-03-04 2025-09-18 AffyImmune Therapeutics Inc. Icam-1 targeted car constructs and methods of treatment
CN118440185B (zh) * 2024-05-22 2024-11-19 宁夏大学 抗bhv-1的重组兔单克隆抗体及双抗体夹心elisa试剂和应用
WO2026038869A1 (ko) * 2024-08-12 2026-02-19 재단법인 아산사회복지재단 암 생존자 유래의 당쇄 특이적 항암 항체
CN119529093B (zh) * 2024-11-29 2026-03-06 武汉爱博泰克生物科技有限公司 一种抗人cd68单克隆抗体及其制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5892644A (ja) 1981-11-26 1983-06-02 Taiho Yakuhin Kogyo Kk 新規なニトロ安息香酸アミド誘導体およびそれを含有する放射線増感剤
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US5624925A (en) 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
US4921963A (en) 1987-04-13 1990-05-01 British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
JPH0819111B2 (ja) 1987-10-22 1996-02-28 ポーラ化成工業株式会社 ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
FI950730A7 (fi) 1992-08-17 1995-04-10 Quadra Logic Tech Inc Menetelmä ei-toivottujen solujen tai kudosten kasvun tuhoamiseksi tai ehkäisemiseksi
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
US5599796A (en) 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
AU4188196A (en) 1994-12-22 1996-07-10 Nissan Chemical Industries Ltd. Organobismuth derivatives and process for producing the same
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5700825A (en) 1995-03-31 1997-12-23 Florida State University Radiosensitizing diamines and their pharmaceutical preparations
GB9816575D0 (en) 1998-07-31 1998-09-30 Zeneca Ltd Novel compounds
GB9818730D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
DE69930328T2 (de) 1998-08-27 2006-12-14 Spirogen Ltd., Ryde Dimere Pyrrolobenzodiazepine
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
GB0416511D0 (en) 2003-10-22 2004-08-25 Spirogen Ltd Pyrrolobenzodiazepines
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7335744B2 (en) * 2003-12-23 2008-02-26 The Regents Of The California University Prostate cancer specific internalizing human antibodies
JP5166861B2 (ja) 2004-03-09 2013-03-21 スピロゲン リミティッド ピロロベンゾジアゼピン
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
PL1879901T3 (pl) 2005-04-21 2010-06-30 Medimmune Ltd Pirolobenzodiazepiny
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US8980833B2 (en) 2007-05-10 2015-03-17 R&D-Biopharmaceuticals Gmbh Tubulysine derivatives
PL2019104T3 (pl) 2007-07-19 2014-03-31 Sanofi Sa Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
GB0813432D0 (en) 2008-07-22 2008-08-27 Spirogen Ltd Pyrrolobenzodiazepines
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US8697688B2 (en) 2010-04-15 2014-04-15 Seattle Genetics Inc. Pyrrolobenzodiazepines used to treat proliferative diseases
MX391454B (es) 2010-04-15 2025-03-05 Seagen Inc Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
EP2580326A1 (en) 2010-06-11 2013-04-17 Antisense Pharma GmbH Method for selective oligonucleotide modification
EP2409983A1 (en) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Tubulysin analogues
CN102372778B (zh) * 2010-08-19 2015-06-17 上海抗体药物国家工程研究中心有限公司 抗人vegf和opn双特异性抗体、其制备方法及用途
CN103269712B (zh) 2010-11-03 2016-09-21 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
CN103648532A (zh) 2011-06-21 2014-03-19 伊缪诺金公司 具有肽连接子的新型美登木素生物碱衍生物及其偶联物
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
CN104244718A (zh) 2011-12-05 2014-12-24 伊格尼卡生物治疗公司 抗体-药物缀合物以及相关化合物、组合物和方法
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
RU2014153674A (ru) * 2012-06-05 2016-07-27 Регенерон Фармасьютикалз, Инк. Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
RU2015129800A (ru) 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
US9701759B2 (en) * 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
WO2014197871A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-drug conjugates, compositions and methods of use
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
EP3126384B1 (en) 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
KR102095096B1 (ko) * 2015-08-26 2020-03-30 바이슨 테라퓨틱스 인크. 다중특이적 항체 플랫폼 및 관련 방법
EA201891732A1 (ru) 2016-02-02 2019-02-28 Кадмон Корпорейшн, Ллк Биспецифичные связывающие белки для pd-l1 и kdr
US12583932B2 (en) 2018-11-16 2026-03-24 Virtuoso Binco, Inc. CD38 and ICAM1 antibodies and uses thereof

Also Published As

Publication number Publication date
CN113302207A (zh) 2021-08-24
US20220002432A1 (en) 2022-01-06
WO2020102777A1 (en) 2020-05-22
JP2022507485A (ja) 2022-01-18
JP2026053336A (ja) 2026-03-25
CN113302207B (zh) 2025-05-13
EP3883967A4 (en) 2023-04-19
JP7785284B2 (ja) 2025-12-15
EP3883967A1 (en) 2021-09-29
US12583932B2 (en) 2026-03-24

Similar Documents

Publication Publication Date Title
CN113302207B (zh) Cd38和icam1抗体及其用途
WO2020114480A1 (en) Anti-claudin antibodies and uses thereof
US11834498B2 (en) Biparatopic FR-alpha antibodies and immunoconjugates
US20210085785A1 (en) Treating cancer by blocking the interaction of vista and its binding partner
CN110087691B (zh) 抗-edb抗体和抗体-药物缀合物
CN112996809A (zh) 结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途
US20220220219A1 (en) Affinity maturated tag72 specific single chaing antibodies
JP2022518150A (ja) 細胞療法での抗ｃｄ４５抗体－薬物結合体（ａｄｃ）の使用経験
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
HK40130188A (zh) Cd38和icam1抗体及其用途
RU2815926C2 (ru) Антитела против клаудина и их применение
WO2025232773A1 (zh) 药物组合及其用途
HK40059021A (en) Anti-claudin antibodies and uses thereof
CN121604979A (zh) 包含效应分子的pd-l1和trop-2靶向缀合物及其用途
HK40059021B (zh) 抗-紧密连接蛋白抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40130188

Country of ref document: HK